Robert W. Baird began coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report sent to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $64.00 price target on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. Roth Capital started coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They set a buy rating and a $60.00 target price on the stock. Zacks Investment Research upgraded Aimmune Therapeutics from a hold rating to a buy rating and set a $34.00 price target on the stock in a report on Wednesday, November 8th. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the stock a buy rating in a report on Saturday, October 21st. BidaskClub lowered Aimmune Therapeutics from a buy rating to a hold rating in a report on Saturday, December 9th. Finally, Credit Suisse Group boosted their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $55.43.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up $2.07 during trading hours on Wednesday, hitting $39.55. The company had a trading volume of 677,166 shares, compared to its average volume of 397,545. The stock has a market capitalization of $2,120.00 and a PE ratio of -16.90. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $39.68.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts predict that Aimmune Therapeutics will post -2.52 EPS for the current year.

In related news, CEO Stephen George Dilly sold 100,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $25.01, for a total transaction of $2,501,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $25.00, for a total value of $500,000.00. Following the transaction, the insider now owns 20,000 shares of the company’s stock, valued at $500,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 274,986 shares of company stock worth $7,533,100. 24.56% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its position in shares of Aimmune Therapeutics by 10.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after acquiring an additional 101,855 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Aimmune Therapeutics by 4.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 110,580 shares of the biotechnology company’s stock worth $2,742,000 after buying an additional 4,891 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Aimmune Therapeutics by 3.4% in the 3rd quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock worth $1,519,000 after buying an additional 2,025 shares during the last quarter. Citadel Advisors LLC grew its stake in shares of Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after buying an additional 542,111 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new stake in shares of Aimmune Therapeutics in the 3rd quarter worth approximately $961,000. Institutional investors own 73.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2017/12/24/aimmune-therapeutics-aimt-coverage-initiated-at-robert-w-baird.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.